July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Choroidal Thickness in Central Serous Retinopathy in Patients with Active and Inactive Disease.
Author Affiliations & Notes
  • Walter I Rivera
    Valley Retina Institute, McAllen, Texas, United States
  • Sarah E Miller
    School of Medicine, University of Texas Rio Grande Valley, Edinburg, Texas, United States
  • Rashed Alhabshan
    Valley Retina Institute, McAllen, Texas, United States
  • Victor H Gonzalez
    Valley Retina Institute, McAllen, Texas, United States
  • Footnotes
    Commercial Relationships   Walter Rivera, None; Sarah Miller, None; Rashed Alhabshan, None; Victor Gonzalez, 60º Pharmaceuticals (F), Abbvie (C), Allegro Ophtalmics (F), Apellis Pharmaceutical (F), Astellas Institute for Regenerative Medicine (F), Bausch and Lomb (C), Bayer (C), Beaver-Visitec International, Inc. (C), Chengdu Kanhong Biothechnology Co.,Ltd. (F), DRCR Net (F), Eyegate Pharma (F), Genentech (C), Genentech (F), Graybug Vision, Inc. (F), Iconic Therapeutics (F), Mallinckrodt ARC Inc. (F), Opthea Ltd. (F), Panoptica (C), Panoptica (I), Regeneron (C), Regeneron (F), Santen (F), Santen (C), Topcon (C), Valeant (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4328. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Walter I Rivera, Sarah E Miller, Rashed Alhabshan, Victor H Gonzalez; Choroidal Thickness in Central Serous Retinopathy in Patients with Active and Inactive Disease.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4328.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Little is known about the comparison of choroidal thickness between active and inactive disease status in patients with central serous chorioretinopathy (CSCR). Our objective is to report choroidal thickness measurements in patients with active and inactive central serous chorioretinopathy.

Methods : This retrospective cohort study included 44 eyes with a diagnosis of central serous chorioretinopathy. The cohort was divided into group A defined as patients who presented with the presence of subretinal fluid on swept-source optic coherence tomography (SS-OCT) (active disease) and group B defined as patients with a history of subretinal fluid without fluid currently seen on SS-OCT (inactive disease). Measurements for choroidal thickness were performed using SS-OCT (Carl Zeiss, Germany). Statistical analysis was conducted using R version 3.5.0.

Results : The mean patient age was 58.8 years and 57.9 for group A and B respectively (ranges from 41-77 years). 22 eyes were included in the group A analysis. 22 eyes were included in the group B analysis. Group A had a mean visual acuity of 20/125. Group B had a mean visual acuity of 20/80 . Group A was found to have a mean choroidal thickness of 384.7 microns (95% CI: 348.4,421). Group B had a mean choroidal thickness of 377.2 microns (95% CI: 338.5,415.9)

Conclusions : Although there was a tendency toward less choroidal thickness in the inactive group versus those with active disease as defined in our study, there was no statistical difference in mean choroidal thickness between the groups.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×